This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.
Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Bacterial Vaginosis Overview
- Therapeutics Development
- Pipeline Products for Bacterial Vaginosis - Overview
- Pipeline Products for Bacterial Vaginosis - Comparative Analysis
- Bacterial Vaginosis - Therapeutics under Development by Companies
- Bacterial Vaginosis - Therapeutics under Investigation by Universities/Institutes
- Bacterial Vaginosis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Bacterial Vaginosis - Products under Development by Companies
- Bacterial Vaginosis - Products under Investigation by Universities/Institutes
- Bacterial Vaginosis - Companies Involved in Therapeutics Development
- Evofem Inc
- Osel Inc
- Starpharma Holdings Ltd
- Symbiomix Therapeutics LLC
For more information about this report visit http://www.researchandmarkets.com/research/qz8d87/bacterial